SynthesisThoracic cancer2026
EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.
Synthesis in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe prognostic significance of EGFR mutations in resected non-small cell lung cancer (NSCLC) remains uncertain despite their established predictive value in advanced disease. We assessed the prognostic impact of EGFR mutation status on recurrence and disease-free survival (DFS) in resected stage I-III NSCLC.
methodsIn this systematic review and meta-analysis, we searched PubMed, Embase, and Cochrane Library to identify studies of resected stage I-III NSCLC reporting recurrence or DFS according to EGFR status. Pooled recurrence rates, risk ratio (RR), and hazard ratio (HR) were calculated using random-effects models. Subgroup analyses were conducted by stage, recurrence site, mutation subtype, and adjuvant treatment.
resultsA total of 20 studies (4 randomized controlled trials and 16 retrospective observational studies), comprising 12 123 patients (7203 EGFR-mutant and 4920 wild-type), were included. Four studies focused on stage I disease, five on stage II-III, and eleven across stage I-III. The pooled recurrence RR comparing EGFR-mutant and wild-type tumors was 1.04 (95% CI, 0.88-1.23), and the pooled DFS HR was 1.07 (95% CI, 0.84-1.37), indicating no significant difference. Recurrence patterns were comparable, with no differences in local or distant relapse and only a modest, non-significant increase in central nervous system recurrence. Among EGFR-mutant tumors, adjuvant EGFR-TKIs improved DFS (HR 0.45, 95% CI, 0.29-0.71) unlike chemotherapy (HR 1.05, 95% CI, 0.67-1.66).
conclusionEGFR mutation status is not associated with recurrence, DFS, or recurrence patterns in resected NSCLC. Adjuvant EGFR-TKIs, but not chemotherapy, confer significant DFS benefit, supporting their use as standard postoperative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.